DEF: Keros Therapeutics Board Seeks Stockholder Approval for Director Elections and Auditor Ratification Amid Strategic Review

Keros Therapeutics is holding its annual meeting to elect directors, ratify auditors, and conduct an advisory vote on executive compensation as the Board evaluates strategic alternatives.

Summary

• Keros Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 4, 2025, in a virtual format.
• Stockholders will vote on the election of three Class II directors, Mary Ann Gray, Ran Nussbaum, and Alpna Seth, each for a term expiring in 2028.
• The meeting will also include a vote to ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote on the compensation of the company's named executive officers (NEOs) will also take place.
• The Board of Directors has initiated a formal review process to evaluate a comprehensive range of strategic alternatives to maximize stockholder value, overseen by a Strategic Committee of independent directors.
• The company's key priorities include continued execution of clinical programs, disciplined capital allocation, and pipeline innovation, with multiple key data and program milestones expected in 2025.
• In October 2024, Dr. Yung H. Chyung was appointed as Chief Medical Officer, and in June 2024, Jean-Jacques Bienaim was appointed to the Board as Lead Independent Director.
• The company entered into an exclusive licensing agreement with Takeda Pharmaceuticals, receiving an upfront payment of $200 million along with future potential milestone and royalty payments.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive developments (Takeda deal, pipeline progress) and challenges (trial discontinuation). The strategic review suggests a proactive approach to maximizing value, contributing to a moderately positive outlook.

Positives

• The exclusive licensing agreement with Takeda Pharmaceuticals provided an upfront payment of $200 million and potential future milestone and royalty payments, strengthening the company's financial position.
• The company is focused on efficiently executing its clinical programs and leveraging data readouts to drive regulatory engagements.
• Keros is maintaining a disciplined approach to capital allocation to deliver enhanced stockholder value.
• The company has a deep bench of executive talent, including the addition of Dr. Yung H. Chyung as Chief Medical Officer in October 2024.
• Jean-Jacques Bienaim was appointed to the Board in June 2024, bringing significant biotechnology and pharmaceutical industry expertise.
• The Board is continuously evaluating ways to enhance stockholder value, including a formal review process to evaluate strategic alternatives.

Negatives

• The Phase 2 clinical trial evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension was discontinued.
• All stock options issued in 2024 were deeply underwater at the time of the annual bonus payout certification.
• The company used its discretion to cap Dr. Seehra's performance-based bonus at 100% of target considering that all stock options issued in 2024 were deeply under water at the time of the annual bonus payout certification.

Risks

• The company is subject to a variety of risks, including those described in the Annual Report on Form 10-K for the year ended December 31, 2024.
• The company faces risks related to financial, accounting, operational, tax, privacy, cybersecurity, and information technology matters.
• There are risks associated with the independence of the Board, potential conflicts of interest, and management and Board succession planning.
• The company's compensation policies and practices may encourage employees to take inappropriate risks.
• The company's clinical programs may not be successful, and data readouts may not support regulatory engagements.

Future Outlook

The company expects multiple key data and program milestones in 2025 and is confident that its innovative science will translate into transformative therapies and long-term growth for stockholders.

Management Comments

• At Keros Therapeutics, our unwavering commitment to innovation and excellence drives everything we do.
• As we develop protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients, we are excited to share our progress and strategic priorities as we look ahead to 2025, a pivotal year for building and enhancing stockholder value.
• The Board appreciates the various stockholder feedback and perspectives heard throughout the year as it informs our efforts to continuously strengthen our governance practices, Board priorities and oversight of the business.

Industry Context

Keros Therapeutics operates in the competitive biopharmaceutical industry, focusing on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-) family of proteins. The company's strategic partnership with Takeda Pharmaceuticals reflects a broader trend of collaborations and licensing agreements in the pharmaceutical sector to advance drug development and commercialization.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like Akero Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals, which are all clinical-stage biopharmaceutical companies.
• The market capitalization range of the peer group (0.3x to 3x of Keros' market cap) is a standard practice in compensation benchmarking to ensure comparability.
• The focus on Phase II companies, particularly in hematology, aligns with Keros' stage of development and therapeutic focus.
• The inclusion of Morphic Holding and Protagonist Therapeutics, and the removal of Fulcrum Therapeutics and Kezar Life Sciences, reflect ongoing efforts to maintain an appropriate peer group based on market capitalization and other relevant criteria.
• The executive compensation practices, including base salaries, bonus targets, and equity awards, are generally consistent with industry standards for similar-sized biopharmaceutical companies.

Management Changes

Corporate Governance

Related Party Transactions

• On April 17, 2025, we entered into a letter agreement with Pontifax Venture Capital regarding the membership and composition of our Board. Pursuant to the Letter Agreement, the Company appointed Mr. Nussbaum to our Board.

Stakeholder Impact

• Stockholders are invited to participate in the Annual Meeting and vote on key proposals.
• The Board is committed to enhancing stockholder value through strategic initiatives and disciplined capital allocation.
• Employees are subject to compensation policies and practices designed to align their interests with those of the company and its stockholders.
• The company's clinical programs aim to deliver meaningful improvements in patient outcomes.

Next Steps

• Stockholders are encouraged to vote by telephone, internet, or mail.
• The Board will continue to oversee the strategic review process and provide updates when available.
• The company will continue to execute its clinical programs and leverage data readouts to drive regulatory engagements.
• The company will continue to monitor all patients in the cibotercept trial and present topline data in the second quarter of 2025.

Key Dates

Keywords

stockholders, directors, Keros Therapeutics, annual meeting, executive compensation, strategic review, clinical trials, pipeline, KER-065, elritercept, cibotercept, Takeda